Evidence map›Paper›PMID 39000050›Full record

ArticleInternational journal of molecular sciences2024

Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain.

Natalia Castrejon, Roberto Martin, Antonio Carrasco, Paola Castillo, Adriana Garcia, Raquel Albero-González, Mireia García, Marta Marginet, Núria Palau, Mónica Hernández and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Natalia CastrejonDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-0647-3058
Roberto MartinDepartment of Medical Oncology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
Antonio CarrascoDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0009-0008-9805-6403
Paola CastilloDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
Adriana GarciaDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
Raquel Albero-GonzálezDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
Mireia GarcíaDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-3445-9744
Marta MarginetDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
Núria PalauMolecular Biology Core Facility, Hospital Clínic, 08036 Barcelona, Spain.
Mónica HernándezDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.
Carla MontironiDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-1453-2193
Guillem ClotAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rosselló 149, 08036 Barcelona, Spain.ORCID 0000-0003-2588-7413
Ana AranceAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rosselló 149, 08036 Barcelona, Spain.
Llucia AlosDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-3460-0384
Cristina TeixidoDepartment of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-7226-6567

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted NGS allows a fast and efficient multi-gene analysis and the detection of key gene aberrations in melanoma. In this study, we aim to describe the genetic alterations in a series of 87 melanoma cases using the oncomine focus assay (OFA), relate these results with the clinicopathological features of the patients, and compare them with our previous study results in which we used a smaller panel, the oncomine solid tumor (OST) DNA kit. Patients diagnosed with advanced melanoma at our center from 2020 to 2022 were included and DNA and RNA were extracted for sequencing. Common mutated genes were

Indexed as

MelanomaMutationAdultAgedAged, 80 and overBiomarkers, TumorFeasibility StudiesFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedProto-Oncogene Proteins B-rafSkin NeoplasmsSpainBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-rafBRAFmelanomamolecular pathwaysnext-generation sequencingNRASoncomine

Identifiers

PMID39000050
PMCPMC11241382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.